By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > SSRI antidepressant > Paroxetine

Paroxetine

GMJ
Last updated: 02/06/2026 14:31
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|638 words

Paroxetine Drug Profile

What is Paroxetine?

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant medication used to treat depression and various anxiety disorders. It belongs to a class of drugs that work by increasing levels of serotonin, a neurotransmitter in the brain that helps regulate mood, emotions, and behavior. Paroxetine is available in both immediate-release and controlled-release formulations.

Uses

Paroxetine is FDA-approved for several mental health conditions:

  • Major depressive disorder: Treatment of episodes of major depression and prevention of relapse
  • Generalized anxiety disorder: Management of excessive worry and anxiety that interferes with daily functioning
  • Panic disorder: Treatment of panic attacks and prevention of future episodes, with or without agoraphobia
  • Social anxiety disorder: Treatment of social phobia and fear of social situations
  • Obsessive-compulsive disorder: Reduction of obsessive thoughts and compulsive behaviors
  • Post-traumatic stress disorder: Treatment of PTSD symptoms including flashbacks, nightmares, and emotional numbing

How it works

Paroxetine works by blocking the reuptake of serotonin in the brain, which means it prevents nerve cells from reabsorbing this important neurotransmitter after it has been released. This action increases the amount of serotonin available in the spaces between nerve cells, enhancing communication between neurons and helping to improve mood and reduce anxiety. The therapeutic effects typically develop gradually over several weeks of treatment.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Nausea and stomach upset
  • Drowsiness or fatigue
  • Dry mouth
  • Dizziness
  • Sexual dysfunction or decreased libido
  • Sweating
  • Constipation
  • Weight gain

Serious side effects requiring immediate medical attention:

  • Serotonin syndrome (high fever, agitation, confusion, rapid heartbeat)
  • Suicidal thoughts or behaviors, especially in young adults
  • Severe allergic reactions with rash, swelling, or difficulty breathing
  • Abnormal bleeding or bruising
  • Severe withdrawal symptoms if stopped abruptly

Warnings and precautions

  • Suicide risk: Paroxetine carries a black box warning for increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults under 25, especially during the first few weeks of treatment
  • Pregnancy considerations: Paroxetine is classified as pregnancy category D, meaning it may cause harm to an unborn baby, particularly heart defects when used during the first trimester
  • Withdrawal syndrome: Discontinuation should be gradual under medical supervision, as abrupt cessation can cause severe withdrawal symptoms including dizziness, flu-like symptoms, and “brain zaps”
  • Liver function: Patients with severe liver impairment may require dosage adjustments as the drug is metabolized in the liver
  • Elderly patients: Lower starting doses may be necessary due to increased sensitivity and slower drug clearance

Interactions

Paroxetine has numerous drug interactions due to its effects on liver enzymes:

  • MAO inhibitors: Dangerous combination that can cause serotonin syndrome; requires at least 14-day washout period
  • Blood thinners (warfarin): Increased bleeding risk due to paroxetine’s effects on platelet function
  • Other serotonergic drugs (tramadol, triptans): Risk of serotonin syndrome when combined
  • Tamoxifen: Paroxetine may reduce tamoxifen’s effectiveness in breast cancer treatment
  • Tricyclic antidepressants: Paroxetine increases blood levels of these drugs, potentially causing toxicity
  • Phenytoin: Reduced effectiveness of this seizure medication
  • St. John’s Wort: Herbal supplement that increases serotonin syndrome risk
  • NSAIDs and aspirin: Increased bleeding risk when used together

Check interactions with the GMJ Interaction Checker

Dosage

Typical adult dosages vary by condition being treated. For depression, the usual starting dose is 20 mg once daily in the morning, which may be increased to 40-50 mg daily if needed. For anxiety disorders, starting doses are often 10-20 mg daily. Panic disorder treatment typically begins at 10 mg daily and may increase to 40 mg daily. Elderly patients usually start with lower doses of 10 mg daily. Dosage adjustments should always be made gradually and under medical supervision. Your healthcare provider will determine the appropriate dose based on your specific condition, response to treatment, and other individual factors.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Paroxetine." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/paroxetine/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Related topics

Optional further reading from the GMJ knowledge base.

In the news
SSRIs show distinct metabolic effects on developing brain cells, Karolinska study reveals
In the news
  • SSRIs show distinct metabolic effects on developing brain cells, Karolinska study reveals · May 20, 2026
Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Evidence review: Which supplements older adults actually need and which ones to avoid

New evidence shows older adults benefit more from targeted supplementation for specific…

Traditional Chinese herb shows promise for androgenetic alopecia treatment

Traditional Chinese herb Polygonum multiflorum shows promise for treating androgenetic alopecia through…

Dual Doctor Couples Face Amplified Childcare Crisis in Medical Training

Dual doctor couples face amplified childcare challenges during medical training, with foundation…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Fluoxetine

By
Prof. Giorgi Pkhakadze
02/06/2026

Citalopram

By
Prof. Giorgi Pkhakadze
02/06/2026

Sertraline

By
Prof. Giorgi Pkhakadze
02/06/2026

Escitalopram

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up